Skip to main content
. 2018 Jul 24;7(15):e008637. doi: 10.1161/JAHA.118.008637

Figure 4.

Figure 4

Reversibility of trastuzumab‐induced decreases in LVEF, (A) related to the trastuzumab treatment regimen: no change in trastuzumab therapy (none), cessation of trastuzumab (held), or permanent stop of trastuzumab (stopped) with and without the addition of cardiovascular medication (added CV meds), and (B) by cardiovascular medications alone (P=0.03 for panel A and P=0.01 for (B) for group comparisons). CV indicates cardiovascular; LVEF, left ventricular ejection fraction.